SK바이오사이언스, 넥스트 팬데믹 겨냥…'범용 백신' 승부수

SK Bioscience is shifting from rapid COVID-19 response to building a universal sarbecovirus platform, reflecting the vaccine industry's evolution toward long-term pandemic preparedness. As WHO and World Bank warn of heightened future pandemic risks, the company's integrated strategy—combining proprietary platform technology with expanded manufacturing through IDT Biologika and its Songdo R&D center—positions it as a critical infrastructure player for next-generation pathogen defense.